Research programme: eye disorder therapeutics - Aerie Pharmaceuticals

Drug Profile

Research programme: eye disorder therapeutics - Aerie Pharmaceuticals

Alternative Names: AR 13154; AR-101; AR-13165; AR-13533; AR-202

Latest Information Update: 04 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Duke University Medical Center
  • Developer Aerie Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors; Janus kinase inhibitors; Norepinephrine plasma membrane transport protein inhibitors; Platelet-derived growth factor beta receptor antagonists; Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Dry age-related macular degeneration; Glaucoma; Neurological disorders; Wet age-related macular degeneration

Most Recent Events

  • 31 Jul 2017 Aerie Pharmaceuticals in-licenses polyesteramide polymers technology from DSM
  • 08 Sep 2015 Aerie Pharmaceuticals and Ramot at Tel Aviv University agree to collaboration on an anti-beta amyloid small molecule product for Neuroprotection and Dry age-related macular degeneration
  • 08 Sep 2015 Preclinical trials in Dry age-related macular degeneration in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top